MDCX · Medicus Pharma Ltd.

Medicus Pharma Ltd. disclosed two material events in this 8-K filing. First, the company entered into Amendment No. 1 to its Equity Distribution Agreement with Maxim Group LLC and Yorkville Securities, LLC, increasing the aggregate offering amount from $15,349,674 to $50,000,000. This upsized ATM program provides the company with greater flexibility to raise capital through at-the-market offerings of its common shares. As of the filing date, approximately $11.5 million had already been raised under the program. Second, on April 21, 2026, the company received a written notice from Nasdaq indicating non-compliance with the minimum bid price requirement (closing bid below $1.00 for 30 consecutive business days). The company has 180 calendar days, until October 19, 2026, to regain compliance by achieving a closing bid price of $1.00 or more for at least ten consecutive business days. If unable to do so, it may qualify for a second 180-day compliance period or face delisting. The company stated it intends to actively monitor the bid price and may implement available strategies to regain compliance. These events are significant for investors as they highlight both the company's capital-raising efforts and a potential listing risk.